ANI intros Cortrophin Gel
ANI Pharmaceuticals is rolling out Purified Cortrophin Gel (repository corticotropin injection) 80 U/mL.
The commercial launch of Cortrophin Gel, an adrenocorticotropic hormone, also known as purified corticotropin, is being led by the company’s recently established rare disease business unit.
“Patients with certain chronic autoimmune conditions often need additional treatment options,” said ANI chief medical officer Mary Pao Seideman. “ACTH therapy can be effective across a number of inflammatory diseases. The reintroduction of Cortrophin Gel gives prescribers another ACTH option, which can mean a greater chance for an effective treatment for some patients.”
[Read more: FDA gives ANI green light for Cortrophin Gel]
Cortrophin gel is indicated for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis and excess urinary protein due to nephrotic syndrome.
“Choice in the ACTH category is long overdue, with only one available treatment option for over two decades. With today’s full-scale commercial launch of Cortrophin Gel, an established treatment, healthcare professionals now have another ACTH therapy option, with U.S.-based development, supply chain and manufacturing,” said Nikhil Lalwani, ANI president and CEO. “This milestone is the culmination of six years of hard work and dedication from ANI employees and external partners, building on ANI’s long history and mission to create high-quality medicines for patients in need. I am extremely proud of the high-degree of technical excellence employed by our team in reintroducing this important treatment to a community long in need of alternatives.”
[Read More: Azurity Pharmaceuticals gets FDA OK for Eprontia]
Cortrophin Gel is now available to healthcare providers through a network of specialty pharmacies and distributors.
“Our goal from the start has been to ensure that Cortrophin Gel is available to as many patients who need it as possible,” said Christopher Mutz, head of rare disease for ANI. “As part of our commitment to supporting meaningful access to Cortrophin Gel, we’ve launched our reimbursement and access support hub, Cortrophin in Your Corner to provide commercial copay support and other reimbursement assistance for eligible patients.”